1. Scrip
  2. >>COVID-19

Coronavirus Update: Moderna’s Vaccine Shows Signs Of Lasting Protection

Plus: Pfizer CEO Relaxed About Vaccine Logistics

 
• By Scrip Team

The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.

Coronavirus stocks
• Source: Shutterstock

Moderna is gearing up for expected emergency use authorizations in the US and elsewhere for its COVID-19 vaccine MRNA-1273 before the end of the year, but is also looking ahead to key questions about how long-lasting protection is from its mRNA-based immunization.

A new update published in the New England Journal of Medicine of Phase I/II of data from the original NIH...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.